Company intelligence / Profile preview

Avesta76 Therapeutics

Los Angeles, California, United Statesavesta76.com ↗

Ownership: Private
Employees: ~9
Development stage: Preclinical

Overview

Avesta76 is developing novel anti-cancer therapeutics that can restore the tumor suppressive function of p53. They have demonstrated tumor regression in more than 12 types of cancer in animal models with no negative side effects. The company is expected to begin clinical trials in 8-12 months (as of the document date)[6].

Therapeutic areas: Oncology
Modalities: Small moleculesMonoclonal antibodies
Industry: Biotech

Drug pipeline

1 asset

Avesta76 cancer masterswitch inhibitor

Preclinical

Beyond the preview

Go deeper on Avesta76 Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Avesta76 Therapeutics.

Explore the full profile